Results 171 to 180 of about 6,146 (182)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

Circulation, 2021
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock   +2 more
exaly  

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure

Circulation, 2021
David M Shavelle, Andrew B Civitello, Mikhail N Kosiborod   +2 more
exaly  

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Nature Medicine, 2022
Stefan D Anker, James L Januzzi, Bela Merkely   +2 more
exaly  

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine, 2015
Bernard Zinman Cm, Christoph Wanner, John M Lachin   +2 more
exaly  

Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Circulation, 2020
Gregory M T Hare, Richard E Gilbert, Nadine Shehata   +2 more
exaly  

Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)

European Journal of Heart Failure, 2020
Kevin Damman, Adriaan A Voors
exaly  

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

New England Journal of Medicine, 2016
Christoph Wanner, John M Lachin, David H Fitchett   +2 more
exaly  

Empagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine, 2023
exaly  

Empagliflozin

Reactions Weekly, 2017
  +4 more sources

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Diabetes and Endocrinology,the, 2013
Michael Roden, Jianping Weng
exaly